Dose 1 of glycopyrrolate, 2.0% QD + Dose 2 of glycopyrrolate, 3.0% QD + Dose 1 of glycopyrronium, 2.5% QD + Dose 2 of glycopyrronium, 3.75% QD

Phase 2Completed
0 watching 0 views this week Active
44
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperhidrosis

Conditions

Hyperhidrosis

Trial Timeline

Apr 1, 2014 → Jan 1, 2015

About Dose 1 of glycopyrrolate, 2.0% QD + Dose 2 of glycopyrrolate, 3.0% QD + Dose 1 of glycopyrronium, 2.5% QD + Dose 2 of glycopyrronium, 3.75% QD

Dose 1 of glycopyrrolate, 2.0% QD + Dose 2 of glycopyrrolate, 3.0% QD + Dose 1 of glycopyrronium, 2.5% QD + Dose 2 of glycopyrronium, 3.75% QD is a phase 2 stage product being developed by Journey Medical for Hyperhidrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02129660. Target conditions include Hyperhidrosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02129660Phase 2Completed

Competing Products

14 competing products in Hyperhidrosis

See all competitors
ProductCompanyStageHype Score
Umeclidinium + VehicleGSK plcPhase 2
51
glycopyrronium Topical WipesJourney MedicalPhase 3
69
Glycopyrronium Topical WipesJourney MedicalPhase 3
69
glycopyrrolate, 1.0% + glycopyrrolate, 2.0% + glycopyrrolate, 3.0% + glycopyrrolate, 4.0%Journey MedicalPhase 2
44
glycopyrronium Topical WipesJourney MedicalPhase 3
69
Glycopyrronium cloth, 2.4% + VehicleJourney MedicalPhase 2
44
BBI-4000 gel, 5% + BBI-4000 gel, 10% + BBI-4000 gel, 15% + Vehicle (Placebo)Botanix PharmaceuticalsPhase 2
44
BBI-4000 Gel, 5% + BBI-4000 Gel, 10% + BBI-4000 Gel, 15% + VehicleBotanix PharmaceuticalsPhase 2
44
BBI-4000, 15%Botanix PharmaceuticalsPhase 2
44
Sofpironium Bromide, 15% + VehicleBotanix PharmaceuticalsPhase 3
69
BBI-4000Botanix PharmaceuticalsPhase 1
25
Sofpironium Bromide Gel, 15% + VehicleBotanix PharmaceuticalsPhase 3
69
Sofpironium Bromide Gel, 5% + Sofpironium Bromide Gel, 15%Botanix PharmaceuticalsPhase 3
69
Sofpironium Bromide Gel, 15%Botanix PharmaceuticalsPhase 2
44